AR111408A1 - Combinación sinérgica de oligonucleóticos de ácidos nucleicos y agentes quimioterapéuticos de análogos de nucleósidos y método de tratamiento - Google Patents
Combinación sinérgica de oligonucleóticos de ácidos nucleicos y agentes quimioterapéuticos de análogos de nucleósidos y método de tratamientoInfo
- Publication number
- AR111408A1 AR111408A1 ARP180100848A ARP180100848A AR111408A1 AR 111408 A1 AR111408 A1 AR 111408A1 AR P180100848 A ARP180100848 A AR P180100848A AR P180100848 A ARP180100848 A AR P180100848A AR 111408 A1 AR111408 A1 AR 111408A1
- Authority
- AR
- Argentina
- Prior art keywords
- splice variant
- gene
- combination
- oligonucleotics
- nucleic acids
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicación 1: Una combinación de agentes antineoplásicos útiles para tratar cáncer que comprende una cantidad eficaz de una o más moléculas de ácido nucleico con capacidad de disminuir la expresión de por lo menos una variante de corte y empalme del gen IG20, en donde no todas las variantes de corte y empalme del gen IG20 están disminuidas, y uno o más quimioterapéuticos análogos de nucleósidos. Reivindicación 2: La combinación de la reivindicación 1, en donde la por lo menos una variante de corte y empalme del gen IG20 se seleccionan de una variante de corte y empalme de MADD, SNP, variaciones alélicas de la misma, polimorfismos de la misma, y mutaciones genéticas de la misma. Reivindicación 3: La combinación de la reivindicación 2, en donde la por lo menos una variante de corte y empalme del gen IG20 es una variante de corte y empalme de MADD que exhibe el exón 13L. Reivindicación 4: La combinación de la reivindicación 2, en donde la una o más moléculas de ácido nucleico con capacidad de disminuir la expresión de la por lo menos una variante de corte y empalme del gen IG20 se seleccionan de ARNpi, ARNhp y oligonucleótidos antisentido.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762489061P | 2017-04-24 | 2017-04-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR111408A1 true AR111408A1 (es) | 2019-07-10 |
Family
ID=63919871
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180100848A AR111408A1 (es) | 2017-04-24 | 2018-04-05 | Combinación sinérgica de oligonucleóticos de ácidos nucleicos y agentes quimioterapéuticos de análogos de nucleósidos y método de tratamiento |
Country Status (3)
| Country | Link |
|---|---|
| AR (1) | AR111408A1 (es) |
| TW (1) | TW201902489A (es) |
| WO (1) | WO2018200145A1 (es) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007084954A2 (en) * | 2006-01-19 | 2007-07-26 | The Board Of Trustees Of The University Of Illinois | Selective inhibition of ig20 splice variants to treat cancers |
-
2018
- 2018-04-03 TW TW107111859A patent/TW201902489A/zh unknown
- 2018-04-05 AR ARP180100848A patent/AR111408A1/es unknown
- 2018-04-05 WO PCT/US2018/026177 patent/WO2018200145A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018200145A1 (en) | 2018-11-01 |
| TW201902489A (zh) | 2019-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ747685A (en) | Oligonucleotide analogues targeting human lmna | |
| MX2022004101A (es) | Composiciones de oligonucleotidos y metodos de uso de las mismas. | |
| CY1124197T1 (el) | Antinohmatika πολυνουκλεοτιδια για να διεγειρεται παραλειψη εξονιου και μεθοδοι θεραπειας δυστροφιων | |
| BR112018011450A2 (pt) | métodos e composições para o tratamento de um transtorno associado à serpinc1 | |
| BR112017013597A2 (pt) | molécula de ácido nucleico, composição farmacêutica, vetor ou célula, e, método para tratamento de uma doença. | |
| MX2024005653A (es) | Agentes de acido ribonucleico (arn) de cadena doble modificados. | |
| BR112018068410A2 (pt) | oligonucleotídeos para redução da expressão de pd-l1 | |
| BR112016029041A8 (pt) | uso de um inibidor de glutaminase, composição farmacêutica e kit farmacêutico | |
| CU24574B1 (es) | Oligonucleótido que contiene una secuencia nucleobase para disminuir la expresión de tau | |
| PH12018500568A1 (en) | Antisense nucleic acid | |
| WO2015106128A3 (en) | Rnai agents modified at the 4'-c-position | |
| BR112017006201A2 (pt) | oligonucleotídeo antisense e composição farmacêutica | |
| EA201791820A1 (ru) | Олигонуклеотидная терапия врожденного амавроза лебера | |
| BR112019003172A2 (pt) | frações de plasma sanguíneo como tratamento para distúrbios cognitivos associados ao envelhecimento | |
| BR112019003731A2 (pt) | aplicação de pridopidina para tratamento de distonias | |
| MX2017004973A (es) | Metodos y composiciones para tratar a un sujeto con un oligonucleotido antisentido de smad7. | |
| BR112018071477A2 (pt) | oligômeros antisenso e métodos de utilização dos mesmos para tratamento de doenças associadas com o gene da alfa-glicosidase ácida | |
| CY1123639T1 (el) | Μονοκλωνα ολιγονουκλεοτιδια για χρηση στην ιατρικη θεραπευτικη αντιμετωπιση διαταραχων του δερματος | |
| PE20211869A1 (es) | Moduladores de la expresion de irf5 | |
| BR112017022578A2 (pt) | agentes nucleosídicos para a redução da atividade deletéria de genes que contém repetições estendidas de nucleotídeos | |
| BR112022012281A2 (pt) | Combinações | |
| AR111408A1 (es) | Combinación sinérgica de oligonucleóticos de ácidos nucleicos y agentes quimioterapéuticos de análogos de nucleósidos y método de tratamiento | |
| BR112022009772A2 (pt) | Métodos e composições para neuroproteção | |
| CL2023000949A1 (es) | Oligonucleótidos antisentido que se dirigen al exón 51 del gen de la distrofina | |
| BR112017021485A2 (pt) | oligonucleotídeo antissentido isolado, composição farmacêutica, métodos para induzir salto de éxon de um rna de sarcoglicano gama, para aliviar distrofia muscular de cinturas tipo 2c, para inibir a progressão de patologia distrófica associada a lgmd2c e para aprimorar função muscular, e, kit. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |